Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ITGB4 |
| Gene Name: | ITGB4 |
| Protein Full Name: | Integrin beta-4 |
| Alias: | CD104; CD104 antigen; GP150; Integrin beta-4; Integrin beta-4C; Integrin, beta 4; ITB4 |
| Mass (Da): | 202151 |
| Number AA: | 1822 |
| UniProt ID: | P16144 |
| Locus ID: | 3691 |
| COSMIC ID: | ITGB4 |
| Gene location on chromosome: | 17q25 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19718 |
| Percent of cancer specimens with mutations: | 1.35 |
| Normal role description: | Integrin alpha-6/beta-4 is a receptor for laminin. Plays a critical structural role in the hemidesmosome of epithelial cells. Is required for the regulation of keratinocyte polarity and motility. Suggested to be involved in invasive carcinoma. Found to promote tumour progression in breast cancer by amplifying ERBB2 signalling in mouse models. |